| Name | Title | Contact Details |
|---|
CuraPharm Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing`s Syndrome (CS).
Sema4 is a rapidly growing patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.
At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology. Founded and headquartered in New York City, we are developing an industry-leading platform to harness the gut-brain axis. Our cross-disciplinary biotechnology team will integrate cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics and consumer products to improve human health and nutrition.
Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.